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Introduction
Hepatocellular carcinoma (HCC) is a devastating disease in which survival is measured in months rather than years from the time of diagnosis.(1) The aggressive nature of the tumour and the usual background chronic liver disease make the management difficult warranting multidisciplinary cooperation. There are many treatment options in hepatocellular carcinoma with none of these proven to be superior to the other. The stage of the disease helps in selecting the ideal treatment option for a particular patient with HCC. ( 2) The incidence of Hepatocellular carcinoma is highest in Asia and Africa, where the high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and Hepatocellular carcinoma.(3-4) While HCC is now being diagnosed early in developed countries as a result of routine follow up with screening procedures which allows early interventions geared towards cure, this is still grossly inadequate in developing countries especially Africa.(5-6) In these patients, local ablative therapies, including radiofrequency ablation, chemoembolization, and potentially novel chemotherapeutic agents, may extend life and provide palliation. (7) Ethanol injection though no longer popular is a good option for us in our centre. It is available, cheap and easily administered under ultrasound guidance.(8) Percutaneous ethanol injection(PEI) treatment, introduced ten years ago as palliative therapy for patients with inoperable hepatocellular carcinoma, can now be used with a curative intent to treat small tumours with results comparable to surgical resection.(9) Made possible by sophisticated radiological techniques, percutaneous ethanol injection became the treatment of choice for patients with poor liver function in whom resection is not possible and local control of the disease is desirable for palliation. (10) For patients with large tumours, or in case of recurrence after previous surgical treatment, a therapeutic approach combining transarterial lipiodol chemoembolization and percutaneous ethanol injection has shown promising results. The number of patients seen at our clinic has increased in the last three years. It is worrisome to note that majority of the patients present late and are suitable only for palliative care aimed at extending as well as improving quality of life in these patients. This study was aimed at evaluating the benefits of percutaneous ethanol injection in the management of advanced hepatocellular carcinoma.
II. Patients and methods
Consecutive patients who had percutaneous ethanol injection for hepatocellular carcinoma at Adoose specialist hospital from August 2008 to July 2012 were prospectively analysed and formed the basis of this study. Excluded from this study were patients with jaundice, flapping tremors and those in coma. Procedures were carried out under ultrasound guidance. The ultrasound was used to localize the tumours and ensure correct needle placement into the tumours before injection. 10-50mls of absolute alcohol manufactured by Riedel-de Haen in Germany was injected percutaneously into the liver tumour(s). The quantity of absolute alcohol injected never exceeded 50mls to prevent intoxication. Injections were repeated fortnightly targeting different parts of the tumour each time in order to achieve symptom control. The site of maximal tenderness was chosen for injection since it represents the point of rapid tumour growth. Information obtained was of the age and sex of the patients, main symptoms and signs at presentation, predisposition to HCC, tumour location and number, stage of the disease, associated paraneoplastic syndromes, Pre and Post-intervention pain scores and survival duration. Data obtained was entered into a proforma and analysed for simple means and percentages using Epi-info version 5.3.2
III. Results
A total of 32 patients had (PEI) during the study period out of an initial 82 that presented with HCC. The mean age of the study population was 40.4+/-14.2yrs with age range of 18 to60yrs. There were 28(87.5%) males and 4(12.5% ) females giving a male: female ratio of 7:1. Right hypochondrial pain and mass were the main symptoms seen in 28(87.5%) patients while 4 (12.5%) had only a mass. The main signs at presentation were tender liver mass in 24(75%) patients, ascites in 2(6.2%) and anaemia in another 2(6.2%). Twenty four (75%) patients had hepatitis B related HCC, 7 (21.9%) had hepatitis C associated HCC while one (3.1%) patient had cryptogenic HCC. Using ultrasound scan, tumours were seen in the right lobe in 20(62.5%) patients, left lobe in 10( 31.3% ) while 2(6.2% )had centrally located tumours. Multiple tumours were seen in22 (68.8%) patients and solitary in 10(31.3%). Mean tumour size was 8.7cm with a range of 7.5 to 21cm. 24 (75%)patients had okuda stage 2 tumours while 8(25%) had stage 3. Sixteen patients (50%) had no paraneoplastic manifestations while 8(25%) had polycythaemia and 4(12.5%) had hypoglycemia while another 4(12%) had skin pigmentation. Pre intervention pain score ranges from 6-8 while post intervention pain score a week after treatment dropped to 1 or 2 (see Table1) . Tabble 1 shows the Pain Scores before PEI and one week after PEI Supplemental systemic analgesia was required in 2() 6.2%) patients post intervention. Longest survivor at follow up with this treatment is 14months with mean survival duration of 8months.
IV. Discussion
The main finding of this study was the significant reduction in pain score by 5-6 points on the Visual Analogue Scale (VAS) noticed in 93.8% which occurred a week after treatment. This is in agreement with the finding by Lin et al who reported relief of abdominal discomfort in all patients with Hepatocellular carcinoma treated with PEI.(11) Bearing in mind that majority of our patients had severe right hypochondria pain associated with a mass as main symptoms at presentation, there is no doubt that PEI is an important modality in the management of advanced Hepatocellular carcinoma. (12) This study also reveals that all the patients presented late as evidenced by the advanced Okuda stage at presentation. This finding is supported by most reported works in Africa and other developing nations. (12) (13) (14) (15) . This late presentation is not surprising since most developing nations do not have dedicated screening programs for HCC. The mean age at presentation in this study was 40yrs; this is a decade earlier than what was reported by Olubuyide 20 years ago in the same country. This may suggest a changing trend in the age of development of HCC in line with the global observation of cancers generally occurring in younger patients. (16) (17) More males appear to be affected in this study than females. This was in agreement with what is generally known about the disease. (18) The mean survival duration in this study was 8 months with the longest survivor so far at his 14 th month of life. This is much better than the 6.3 months reported by Manterola et al.(19) the average survival at diagnosis of hepatocellular carcinoma is six months without intervention. This treatment option appears to prolong survival though marginally. Half of the patients in this study had associated paraneoplastic syndromes which is in consonance with that reported by Teniola et al.(20) This implies that paraneoplastic syndromes are common in patients with HCC and should be sought in the management of these patients. We conclude that percutaneous ethanol injection significantly reduces the pain of advanced hepatocellular carcinoma and prolongs survival. We strongly recommend establishment of dedicated screening centres for early detection of Hepatocellular carcinoma.
V. Conclusion
Percutaneous ethanol injection significantly reduces the pain of advanced hepatocellular carcinoma and prolongs survival.
